Topical application of certain petroleum middle distillates (PMD) to mice produces skin tumors after long latency, and initiation/promotion protocols indicate that this effect is associated with their tumor promoting activity. Since induction of sustained, potentiated epidermal hyperplasia is predictive of promoting activity, five compositionally distinct PMD [hydrodesulfurized kerosene (API 81-07); hydrodesulfurized PMD (API 81-10); odorless light petroleum hydrocarbons; severely hydrotreated light vacuum distillate (LVD); and lightly refined paraffinic oil (LRPO)] were assessed for their effects on epidermal hyperplasia. PMD were administered (2 x/week for 2 weeks) to skin of CD-I mice. Four quantitative biomarkers of epidermal hyperplasia were evaluated: epidermal thickness, number of nucleated epidermal cells per unit length of basement membrane, labeling (BrdUrd) index of epidermal cells, and induction of epidermal ornithine decarboxylase (ODC) activity. As positive controls, 12-0-tetradecanoylphorbol-13-acetate (TPA) and n-dodecane were utilized. PMD-induced skin irritation was evaluated visually and/or histopathologically. All five PMD produced dose-dependent, skin irritation and epidermal hyperplasia. On a weight basis the magnitude of the maximal PMD-induced effects was similar to that produced by n-dodecane, but > 1000-fold less than that produced by TPA. Epidermal hyperplasia and subacute skin irritancy produced by the five PMD were similar. Of the four short-term markers of tumor promotion assessed, labeling index and epidermal ODC activity were predictive of the relative promoting activities of those PMD for which tumorigenicity bioassay data are available, i.e., API 81-07 > API 81-10 > LRPO. An apparent discrepancy to the predictability of epidermal ODC activity occurred with LRPChtoluene [1:1 (v/v)]. This mixture is nontumorigenk, yet significantly induced epidermal ODC activity. This mixture, however, produced severe epidermal toxicity that precluded any meaningful analysis of short-term biomarkers in relationship to biological activity, o \<m socim of Toxicology.
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1 A preliminary report of this research was presented at the Seventh International Conference on Carcinogenesis and Risk Assessment, December 1993, Austin, Texas (Skisak et al., 1995) . 2 To whom correspondence should be addressed. Several investigations have demonstrated that certain PMD, 3
i.e., straight run distillates and their refined products boiling in the range 170°-370°C, exhibit tumorigenic activity when administered chronically to mouse skin (Lewis, 1983; Witschi et al, 1987; Biles et al, 1988; Skisak et al, 1994; Broddle et al, 1996) . These PMD are complex mixtures of linear and branched aliphatics, olefins, cycloparaffins, and aromatics in the C10-C16 range, and due to their distillation temperatures contain very low levels of PAC having three or more fused rings (Biles et al, 1988; Skisak, 1991) . When PMD, deemed nonmutagenic by the Modified Ames Assay (Blackburn et al, 1986) , have been submitted to bioassay in initiation/promotion protocols using mouse skin, only tumor promoting activity has been observed (McKeeef al, 1989; Skisak, 1991; Skisak et al, 1994; Jungen et al, 1995) , suggesting that the tumorigenic activity of these PMD may be due to promotion of preexisting, spontaneously initiated cells (McKee et al, 1989; . Although subacute (Grasso et al, 1988; Freeman et al, 1990) and chronic (Biles et al, 1988; Gerhart et al, 1988; Skisak, 1991; Freeman et al, 1993; Jungen et al, 1995; Broddle et al, 1996) topical exposure of mice to PMD produces skin irritation, the role of skin irritancy in the tumorigenic response is still not clear; e.g., Freeman et al, (1993) and Broddle et al, (1996) were not able to demonstrate a good correlation between skin irritancy and tumorigenicity for PMD subjected to chronic bioassay using the mouse skin model. On the other hand, accumulating evidence indicates that the sustained epidermal hyperplasia that accompanies subacute PMDinduced skin irritation may play an important role in PMDinduced tumor promotion (Grasso et al, 1988; Biles et al, 1988; Gerhart et al, 1988; Skisak, 1991; Freeman et al, 1993; Jungen et al, 1995) .
A qualitative correlation between sustained, potentiated epi-dermal hyperplasia and tumor promotion in mouse skin has been established for a number of structurally diverse chemicals (Argyris, 1985 (Argyris, , 1989 Naito et al., 1987; Kruszewski et al., 1989; DiGiovanni, 1992) . Chemically induced epidermal hyperplasia has been quantified as increases in epidermal thickness, number of epidermal cells per unit length of basement membrane, and the labeling index of epidermal cells (Naito et al., 1987) . In addition, epidermal ODC activity is induced by tumor promoters and contributes to the proliferative stimulus by increasing epidermal putrescine and spermidine (O'Brien et al., 1975a,b; Kruszewski and DiGiovanni, 1988) . Furthermore, since effects on these biomarkers can be adequately evaluated following only 2 weeks of repetitive treatments with a tumor promoter (DiGiovanni, 1992) , they potentially represent a rapid and cost-effective method to obtain information on the promoting activity of PMD. The potential utility of sustained epidermal hyperplasia in predicting the tumorigenicity of oil products topically applied to mouse skin was demonstrated by Darmer et al. (1992) . Although limited to a single PMD, Skisak (1991) demonstrated a similar dose-dependence for PMD-induced epidermal hyperplasia and skin tumor promotion. The studies reported herein extend the observations of Skisak (1991) by examining the effects of five PMD of varying chemical composition on skin irritancy and sustained, potentiated epidermal hyperplasia, using short-term topical exposures of mice, and, where possible, correlating these effects with their reported tumorigenic activities in chronic and initiation/promotion bioassays.
The study reported here is an integral component of a larger investigation to improve the basis for cancer risk assessment of PMD to humans. The study was designed to identify relevant biomarkers and provide a baseline for correlative investigations using human skin xenografted to immunodeficient mice. API 81-07 and API 81-10 have been previously described in reports by the American Petroleum Institute (1988a,b) and by Skisak et al., 1994. In the latter reference API 81-07 was referred to as hydrodesulfurized kerosene and API 81-10 as hydrodesulfurized middle distillate. LRPO has been previously described (McKee et al, 1989; Freeman et al, 1990 Freeman et al, , 1993 Przygoda et al., 1994) .
MATERIALS AND METHODS
The physicochemical properties of the PMD test articles are summarized in Table 1 . For API 81-10 the content of PAC containing >3 fused rings was determined by gas/liquid chromatography and mass spectroscopy (EPA Method 8270). Only pyrene (659 mg/kg) was detected. The following components were not detected, i.e., <10 mg/kg: fluoranthene, benz(a)anthracene, chrysene, 7,12-dimethylbenz(a)anthracene, benzo(b)fluoranthene, benzo(k)fluoranthene, benzo(a)pyrene, dibenz(aji)anthracene 1 indo(l,23-cd)pyrene, and benzo(g,h,i)perylene.
A mixture of LRPO and toluene [l:l(v/v) ] was also evaluated, since Freeman et al (1993) had reported that dilution of LRPO in toluene reduced its tumorigenicity in the mouse skin model. The following test articles were utilized as positive controls for irritancy and hyperplasiogenic effects in mouse skin; TPA, 99+% pure, obtained from LC Services, Inc. (Woburn, MA) and n-dodecane, obtained from Aldrich Chemical Co. (Milwaukee, WT). Acetone (99.6% pure, Mallinckrodt Chemical Co., Chesterfield, MO) and toluene (99.7% pure, Aldrich Chemical Co.) were utilized as solvent controls.
Bacterial mutagenicity of PMD test articles. The mutagenicity of API 81-07, API 81-10, OLPH, and LVD was assayed by the Modified Ames Assay (Blackburn et al, 1986) using Salmonella typhimurium strain TA98. The test system utilized an enzyme-rich extract (termed S-9) derived from Syrian Golden Hamster liver, prepared by and purchased from Molecular Toxicology, Inc. (Boone, NC). Testing was performed essentially as described in ASTM Standard Method E 1687-95 and used five concentrations of each dimethyl sulfoxide extract of the four PMD test articles. The slope of the dose response (i.e., the mutagenic index, Ml) was determined by linear regression analysis. By convention, any MI > 2.0 is considered mutagenic. The MI of LRPO was derived from data reported by Pryzgoda et al. (1994) ; however, the value reported here was recalculated by Exxon using linear regression analysis.
Experimental animals. Specific-pathogen-free, female CD-I mice (4-6 weeks of age) were obtained from Charles River Laboratories, Quebec, Canada, and placed in quarantine for 3 weeks prior to entry onto protocol. The mice were group housed (3/cage) during the first 2 weeks of quarantine. During the last week of quarantine and while on protocol, mice were housed singly in stainless steel cages. Near the end of quarantine the mice were uniquely identified using numbered ear tags and randomly assigned to experimental groups. Mice were provided feed (pelletized Purina 5002 Certified Rodent Chow) and water (filtered and deionized) ad libitum. The housing environment was maintained at 21-23°C and a relative humidity of 55-57% and employed a 12-h light/12-h dark cycle with lights on from 0600 to 1800. The experimental animal facility was AAALAC accredited and caging complied with ILAR/AAALAC requirements.
Formation of experimental groups and dosing of mice.
Because of the logistics of dosing and the timely collection of skin specimens at termination, the test articles were evaluated in two separate experiments: sham, acetone, toluene, API 81-07, API 81-10, n-dodecane, and TPA in Experiment 1 and acetone, toluene, OLPH, LRPO, LRPO:toluene [l:l(v/v)], LVD, n-dodecane, and TPA in Experiment 2. Mice were entered onto protocol at 7-9 weeks of age. At termination of the quarantine period, the backs of the mice were shaved using an Oster electric shaver equipped with a No. 40 clipper blade. Shaving was performed in a manner to minimize skin abrasion. Multiple shavers were used and the blades frequently changed to avoid heating the skin. Shavers were cleaned using only a brush and ethanol. Two days after shaving, the mice were examined and any mice exhibiting dermal abrasions or hair follicles in the active growth phase were excluded from entry onto protocol. Mice were randomly assigned to experimental groups (16/group) such that the group mean body weights were within the following ranges, i.e., 24.8 ± 0.3 g in Experiment 1 and 27.4 ±0.1 g in Experiment 2. The body weights of mice used in the experiments ranged from 21.5 to 28.3 in Experiment 1 and from 23.5 to 31.4 g in Experiment 2. All test articles, except the solvent controls and the LRPO:toluene mixture, were tested at four concentrations. PMD were tested undiluted (neat) and diluted with acetone, while TPA and n-dodecane were tested at four concentrations diluted in acetone. The stock solution of TPA was prepared on the first day of dosing and stored at -20°C. Dilutions of TPA and other test articles were prepared fresh each day prior to dosing. The solvent controls and test articles diluted in acetone were applied to the interscapular/lumbar region of the back [an elliptical area (approx. 8 cm 2 )
having a maximum length and width of 4 and 2.5 cm, resp., and its long axis centered on the midline, i.e., the skin above the spinal column] in a total volume of 200 /xl. Neat doses were applied as 100 /il, but spread over the same surface area. Test articles and vehicle controls were dosed between 0800 and 1200 on Days 1, 5, 8, and 12 on protocol.
Visual assessment of skin irritation. All mice were observed for gross signs of skin irritancy at Days 2,6, 9, and 16 on protocol. Each of the following parameters was scored for seventy on a scale of 0-3 (minimal, 1; moderate, 2; marked, 3): erythema, edema, desquamation, eschar, discoloration, fissunng, and ulceration. A composite score, i.e., the sum of the parameter scores, was calculated for each mouse. The sum of the composite scores for mice in each experimental group was divided by the number of mice in each experimental group to obtain the group mean score. At Days 2, 6, and 9 each group contained 16 mice, while at Day 16 each group contained only 4 mice, since 75% of the mice had been terminated by that time. To allow comparison between experiments, responses were normalized to a percentage of that produced by 13.6 nmol TPA.
Collection of skin specimens. At 6, 24, 48, and 96 h after final dosing 4 mice, randomly selected from each experimental group, were terminated by cervical dislocation. Thirty minutes prior to the sacrifices at 24, 48, and 96 h after final dosing, mice received ip injections containing 100 (xg BrdUrd/g body weight. BrdUrd (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile phosphate-buffered saline 1 h before dosing and administered in 0.1-0.2 ml. Following termination, the mice were shaved (if required) and a depilatory (Nair) was applied to the dosed area of skin. After 5 min, the depilatory was removed by gentle scrubbing with a gloved finger under running tap water. The mice were placed in a pan of ice (dorsal side down) until excision of the dosed skin. An elliptical section of dosed skin was excised and spread on a cutting board. A template was used to subdivide the skin specimen. The excised skin was divided into anterior and posterior sections by cutting perpendicular to the midline at a distance 2.5 cm below the anterior end of the specimen. From the anterior section two rectangular skin specimens (05X2 cm) were excised, each having one 2-cm side along the midline and a posterior 0.5-cm edge from the initial dividing cut. Each of these specimens was placed in a cassette and preserved in buffered Formalin. A 1-cm 2 section, having its anterior edge bisected by the midline, was excised from the posterior section of skin. This specimen was further processed for assay of epidermal ODC activity. As a backup, dosed skin peripheral to the above described specimens was quick frozen on a block of frozen optimal cutting temperature compound (Tissue Tek, Miles, Inc., Elkhart, IN) and stored in liquid N 2 .
Processing of skin specimens for histopathologic and histomorphic assessments. The Formalin-fixed tissues were embedded in paraffin and processed for histopathologic and histomorphic assessment Care was taken to assure that tissue sections were cut perpendicular to the plane of the skin. H&E-stained sections were prepared from Formalin-fixed skin specimens from all mice terminated 24 and 48 h after final dosing in Experiment 1 and for all mice terminated 24,48, and 96 h after final dosing in Experiment 2. A problem of indeterminate origin in the processing of Formalin-fixed skin specimens from mice terminated 96 h after final dosing in Experiment 1 precluded evaluation of those specimens; consequently, frozen skin specimens were thawed, fixed in Formalin, embedded in paraffin, and processed for histopathologic and histomorphic assessment. Histopathologic assessment of skin irritation followed guidelines, established by the U.S. Environmental Protection Agency (1990) , to assess maximum tolerated dose of topically applied material. The following areas of the tissue section were avoided during histomorphic assessments: (1) the extreme edges of the section; (2) areas exhibiting microulceration, necrosis, inflammation, or histologic artifact; and (3) areas of epidermal sloughing. No histomorphic assessments were made on tissue sections exhibiting epidermal sloughing over a 25% of its surface.
Histopathologic assessment of skin irritation and epidermal hyperplasia.
For assessment of irritation of the epidermis and dermis, each of the following parameters was scored for severity on a scale of 0-5: erosion, ulceration, crust formation, epidermitis, necrosis/acantholysis, spongiosis/hydropic degeneration, and intraepithelial pustule formation for epidermal irritation; and inflammatory infiltrates, edema, and vasodilanon for dermal irritation. For assessment of epidermal hyperplasia, each of the following parameters was scored on a scale of 0-5: orthokeratosis, parakeratosis, hyperplasia, and dyskeratosis. Score rankings for seventy were as follows: minimal, 1; mild, 2; moderate, 3; marked, 4; and severe, 5. Separate composite scores for epidermal or dermal irritation and epidermal hyperplasia, i.e., the sum of the respective parameter scores, were calculated for each mouse. The sum of the composite scores for mice in each experimental group was divided by the number of mice/group to obtain the group mean score. To allow comparison between experiments, responses were normalized to a percentage of that produced by 13.6 nmol TPA.
Quantitative evaluation of epidermal hyperplasia. Quantitative evaluation of epidermal thickness and the number of nucleated epidermal cells per unit length of basement membrane was performed by microscopic examination of H&E-stained sections of mouse skin. Epidermal thickness is expressed as the mean of separate measurements of the thickness (^im) of the interfollicular, noncornified epidermis made in 10 random 40 X fields. The number of nucleated epidermal cells per unit length of basement membrane is expressed as the mean from five separate 100-^im segments of basement membrane, excluding cells with nuclei overlapping by more than 50% of their area and intraepithelial polymorphonuclear cells or lymphocytes. The methodology followed essentially that described by Naito el al. (1987) .
Measurement of labeling index. Proliferation of epidermal cells was also measured as a function of the number of epidermal cells incorporating BrdUrd into their DNA. The methodology employed followed essentially that described by Sugihara el al. (1986) , except that an alkaline phosphatase detection system (Supersensitive Multilink-HRP/AEC from Biogenex, San Ramone, CA) was employed. The monoclonal antibody against BrdUrd (Becton-Dickenson, San Jose, CA) was utilized at a dilution of 1:200. A total of 500 epidermal basal cells (labeled and unlabeled) adjacent to the basement membrane were evaluated and the labeling index was expressed as the percentage of labeled cells.
Assay of ODC activity. Epidermal ODC activity was measured essentially according to the method of Kmszewski and DiGiovanni (1988) , using the liberation of I4 CO 2 from [ 14 C]ornithine. Enzyme activity is expressed as nmol CO 2 liberated/mg protein/h. Unfixed skin specimens (1 cm 2 ) from each mouse were placed on a cold glass plate and the epidermis was scraped from the underlying dermis. The scrapings from four mice in each treatment group were pooled and homogenized (4°C) in 2 ml of the buffer desenbed by Kmszewski and DiGiovanni (1988) , using a polytron homogenizer (2 X 15 s). The homogenate was centrifuged at 30,000g for 30 min. The supematants were stored at -70°C until use in the assay. Each supernatant was assayed using replicate 100-jtl aliquots. The protein content of the supematants was determined using the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Richmond, CA).
Statistical analysis. Statistical analysis of variation within and between treatment groups was performed using the Mann-Whitney test (GRAPH PAD INSTAT Version 1.0). Such analysis was performed on the following quantitative parameters: epidermal thickness, nucleated cells/unit basement membrane, and labeling index.
RESULTS

Mutagenicity of PMD Test Articles
The mutagenicity indices of the PMD test articles are shown in Table 1 . 
Clinical Observations of Mice on Protocol
With the exception of skin irritation, no treatment-related clinical signs of toxicity were observed while the mice were on protocol. All mice survived until scheduled necropsies, except two mice in Experiment 2 assigned to termination at 96 h after final dosing (33 /xl LVD and 100 /xl OLPH) that were accidentally killed on Day 1 following dosing. Group mean body weight gains while on protocol were within the expected ranges: 1.6-2.9 g between Days 2 and 12 in Experiment 1 and 0.6-1.9 g between Day 2 and termination in Experiment 2.
Gross Visible and Histopathologic Assessments of Test Article-Induced Skin Irritation and Epidermal Hyperplasia
These semiquantitative assessments are summarized in Table 2. From Days 6 to 16 on protocol the PMD and rc-dodecane produced visible skin irritation that was directly dose-dependent and increased in severity as a function of time on protocol. PMD and n-dodecane (neat or diluted in acetone) produced only erythema and edema and no mouse exhibited more than a moderate effect for any single parameter. Although histopathologic assessment of skin irritation produced by the PMD or n-dodecane (neat or diluted in acetone) indicated that maximal effects in some cases exceeded that produced by 13.6 nmol TPA, no mouse exhibited a severity score greater than 3 for any single parameter. The LRPO:toluene mixture produced the most severe skin irritation, in some cases producing epidermal sloughing. Only the histologic evaluations using skin collected 48 h after final dosing are shown, since these were generally representative of the maximal effects observed. Table 3 summarizes the quantitative assessments of epidermal thickness, the number of nucleated epidermal cells per unit length of basement membrane, and the labeling index of epidermal cells. Only the assessments using skin collected 24 or 48 h after final dosing are shown, since those selected were generally representative of the maximal effects observed. The effects of the PMD and n-dodecane on these parameters were generally dose-dependent. In some cases, however, maximal or near maximal responses were produced by the higher doses.
Histomorphic Assessments of Test Article-Induced Epidermal Hyperplasia
Induction of Epidermal ODC Activity by the Test Articles
The ability of the test articles to induce epidermal ODC activity is shown in Table 4 . All PMD-and n-dodecaneinduced ODC activity at 6 h after final dosing and the effects produced by these test articles diluted in acetone were directly dose-dependent, except for API 81-10, where the two lowest doses exhibited a similar response. The enzyme inductions of the PMD and n-dodecane were transient, since in all cases ODC activities fell substantially or returned near to control levels by 24 h after final dosing.
Because epidermal ODC induction occurs within a short time frame (O'Brien and Diamond, 1977; Baxter and Miller, 1987) , small differences in the time between final dosing and skin specimen collection can result in relatively large differences in absolute values. In addition, the enzyme assay is subject to inherent variabilities in basal ODC activities, making comparisons between experiments difficult. For these reasons the activities of the two highest doses of each test article have been expressed as a percentage of the activity induced by 13.6 nmol TPA, a positive control included in both experiments.
DISCUSSION
The objective of this research was to identify short-term biomarkers of tumor promotion that best reflect quantitatively the tumorigenic properties of PMD in the mouse skin model. The long-range purpose is to use this information in correlative studies to improve the risk assessment for PMD tumorigenicity in humans. Five PMD differing in chemical properties were investigated. Three of these five PMD (API 81-07, API 81-10, and LRPO) had previously been subjected to bioassay of their tumorigenicity in the mouse skin model (Skisak, 1991; Skisak et al, 1994; McKee et al, 1989) . See Table 5 . All three induced skin tumors with long latency in complete carcinogenesis bioassays, but only exhibited tumor promoting activity in initiation/promotion bioassays.
Of the five PMD investigated, only API 81-10 exhibited mutagenic activity in the Modified Ames Assay (Table 1) as defined by ASTM Method El687-95. This mutagenic activity was not accompanied by demonstrable tumor initiating activity in the mouse skin bioassay, since the incidence of skin tumors produced by API 81-10 in a initiation protocol was not significantly different from that of the TPA control (Skisak et al, 1994) . CONCAWE (1991), Roy et al. (1988), and previously reported a lack of correlation between mutagenicity and tumor response in mouse skin for PMD. Also, Jungen et al. (1995) were unable to detect tumor initiating activity in a PMD having an MI similar to that of API 81-10. Typically the mutagenic response of petroleum distillates with median boiling points above 26O°C correlates directly with their PAC content (Roy et al, 1988) . It is, however, unclear how API 81-10 elicits a mutagenic response, since it contains very low levels of PAC. Pyrene, the only PAC with >3 fused rings detected in API 81-10, is not mutagenic to the TA98 strain of S. typhimurium [International Agency for Cancer Research (1983) ]. In fact, none of the physicochemical parameters, including the content of n-dodecane, a known tumor promoter (Sice, 1966) , can explain the tumorigenic properties of the three PMD. The most adequate explanation for the tumorigenic activity of API 81-07, API 81-10, and LRPO remains their promotion of preexisting, spontaneously initiated cells (McKee et al, 1989; Przygoda et al, 1994 ). This appears to be an adequate explanation even for some of those PMD, like API 81-10, that contain very low levels of PAC, but still exhibit mutagenic activity in the Modified Ames Assay.
All five PMD produced skin irritation and epidermal 18.9 ±0.7* 36.0 ± 4.5* 40.0 + 4.9* 16.3 ± 2.5 25.7 ± 1.6* 45.0 ± 5.9* 52.3 ± 4.2* 51.2 + 3.6* 17.6 ± 1.9 37.4 ± 6.9* 37.4 ± 3.6* 43.4 + 2.9* 15.7 + 1. hyperplasia, the latter measured by increases in epidermal thickness, the number of nucleated epidermal cells per unit of basement membrane, the labeling index of epidermal cells, and the induction of epidermal ODC activity (summarized in Table 5 ). Although all of the biological responses may be relevant to tumorigenesis, not all the responses correlated with the relative tumor promoting activities of API 81-07, API 81-10, and LRPO. For example, similar to the observations of Freeman et al. (1993) and Broddle et al. (1996) , skin irritancy was not predictive of the relative tumorigenic activities of the three PMD. In the study reported here, relative skin irritancy was inversely related to tumor promoting activity. The relative skin irritancies of the three PMD was LRPO > API 81-10 > API 81-07, as measured by gross visual assessment or histologic evaluation of the epidermis (see Table 2 ), while relative tumor promoting activity is API 81-07 > API 81-10 > LRPO (see Table 5 ). Epidermal hyperplasia, measured by histologic assessment or as epidermal thickness, also related inversely to relative tumor promoting activity (Table 5) . Measurements of the number of epidermal cells per unit of basement membrane yielded the following relative epidermal hyperplasiogenic activities: LRPO > API 81-07 > API 81-10 (Table 5) . Quantitative measurements of labeling index and epidermal ODC activity did, however, correlate well with their relative tumor promoting activities, i.e., API 81-07 > API 81-10 > LRPO. See Fig. 1 and Table 5 . Although limited to only three PMD, the data suggest that the labeling index of epidermal cells and the induction of epidermal ODC activity represent the most appropriate biomarkers for predicting the relative tumor promoting activities of PMD in mouse skin. Increased epidermal ODC activity was also observed in mice treated with the LRPOitoluene mixture (Table 4) , which suggests that this mixture could be tumorigenic in the mouse skin model, using the above criteria. However, Freeman et al. (1993) , reported that the LRPO:toluene mixture was not tumorigenic in a complete carcinogenesis bioassay using the mouse skin model. To explain this apparent contradiction it should be noted that short-term topical exposure to toluene as described here produced severe epidermal toxicity, as evidenced by epidermal sloughing. Epidermal toxicity is also evidenced by the low epidermal labeling index induced at 24 h by the LRPO:toluene mixture (5.8%), compared to 18.1% for neat LRPO (see Table 3 ). It can be speculated that the use of toluene as a diluent for LRPO may have decreased LRPO-induced tumor promotion by toxicity to the skin, an action that decreased the number of spontaneously initiated cells. Thus, under conditions of severe epidermal toxicity ODC activity may be an unreliable predictor of the tumorigenic potential of PMD. In contrast, epidermal labeling index measured at 24 h after the last dose may more accurately predict tumor promoting activity among PMD.
In conclusion, five PMD of varying chemical composition all produced subacute skin irritation and epidermal hyperplasia upon short-term topical application to mouse skin. All evidence to date indicates that tumor promoting activity of certain PMD occurs secondary to chronic, repeated irritation or toxicity to the skin. However, gross scoring methods of skin irritation or epidermal hyperplasia do not result in correlations with tumor promoting activity. On the other hand, two measures of PMD-induced epidermal hyperplasia [i.e., the labeling (BrdUrd) index of epidermal cells and the induction of epidermal ODC activity] correlated closely with their relative promoting activities. Studies with toluene and LRPO diluted in toluene indicated that toluene exacerbated LRPO-induced skin toxicity, producing epidermal sloughing. Thus, although LRPO diluted with toluene induced significant elevation of epidermal ODC activity, severe epidermal toxicity may limit its tumor promoting activity. This suggests that epidermal ODC activity as a biomarker of PMD-induced tumor promotion in mouse skin can be meaningfully interpreted only in the absence of epidermal toxicity. In addition, the data presented here suggest that the labeling index of epidermal cells, measured at 24 h after the last dose, may be a better overall predictor of tumor promoting activity among PMD. Further studies with LRPO diluted with toluene and other PMD should shed light on these issues. " Net mean maximal response above that produced by the acetone control, expressed as a percentage of the net mean maximal response produced by TPA. * BM, basement membrane. c Net mean maximal response, expressed as a percentage of the net mean maximal response produced by TPA. rf Skisak el al. (1994) . The promotion bioassay utilized male CD-I mice. Initiation was achieved by a single topical application of DMBA (50 /xg in 50 /xl acetone). Following initiation, 50 /xl PMD (neat) was applied 2X/week for 25 weeks.
" McKee et al. (1989) . The promotion bioassay utilized male CD-I mice. Initiation was achieved by a single application of DMBA (50 /xg in 25 fi\ acetone). Following initiation, 25 /xl PMD (neat) was applied 3X/week for 25 weeks.
•^ Baxter and Miller (1987) . The promotion bioassay utilized female SENCAR mice. Initiation was achieved by a single topical application of DMBA (10 nmol in 200 /xl acetone). Following initiation, /i-dodecane (50 mg in 200 fi\ acetone) was applied 2X/week for 25 weeks.
* Skisak (1991) . The promotion bioassay utilized male CD-I mice. Initiation was achieved by a single application of DMBA (50 /xg in 50 /xl acetone). Following initiation, TPA (5 /xg in 50 /xl acetone) was applied 2X/week for 25 weeks. 
